Non-opioid Pain Treatment Market (By End User: NSAIDs, Acetaminophen, Local Anesthetics, Others; By Administration Analysis: Chronic Pain, Post-operative Pain, Cancer Pain, Others; By Route of Administration: Oral, Topical, Injectable, Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Non-opioid Pain Treatment Market, by Drug Class, 2024-2034
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Acetaminophen
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Local Anesthetics
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Non-opioid Pain Treatment Market, by Pain Type, 2024-2034
9.1.1. Chronic Pain
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Post-operative Pain
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Cancer Pain
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2024-2034
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dr. Reddy’s Laboratories Ltd
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GSK plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Perrigo Company plc,
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. LNK International, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cipla Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Services, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client